Uniparental foetal disomy: invasive diagnosis

Test covered by the reimbursement:
YES
Gender:
Woman
Material:
Chorionic villi, Amniotic fluid
Turnover time:
10 days
STATIM:
7 days

Material:

Chorionic villi | Chorionic villi, min. 30 mg tissue in a microtube (Eppendorf type)
Storage after examination: week after the report is issued 2 – 8°C
Amniotic fluid | 3x 10 ml of amniotic fluid in a tube
Storage after examination: week after the report is issued 2 – 8°C
Cord blood | 2–3 ml of cord blood in EDTA
Storage after examination: week after the report is issued 2 – 8°C
Isolated DNA from chorionic villi | 30–100 ng/μL of isolated DNA from chorionic villi in a microtube (Eppendorf type)
Storage after examination: stored in a DNA archive without restriction 15°C
Isolated DNA from amniotic fluid | 30–100 ng/μL of isolated DNA from amniocentesis in a microtube (Eppendorf type)
Storage after examination: stored in a DNA archive without restriction 15°C
Isolated DNA from cordocentesis | 30–100 ng/μL of isolated DNA from cordocentesis in a microtube (Eppendorf type)
Storage after examination: stored in a DNA archive without restriction 15°C
Cultured cells | 1.5 ml of cultured cells in a microtube (Eppendorf type)
Storage after examination: 180 days 2 – 8°C
DNA isolated from cultured cells | 30–100 ng/μL of isolated DNA from cultured cells in a microtube (Eppendorf type)
Storage after examination: stored in the DNA archive 15°C

Quick test description:

Genetic testing aimed at demonstrating that for each pair of chromosomes, one chromosome originating from the mother and one from the father is present in the foetus.

Test details:

The principle of the SNP array is the hybridization of engineered tested DNA (amplification, fragmentation, precipitation and resuspension) to immobilised probes on the chip, specific labelling with a fluorescent dye and subsequent scanning of the fluorescent signal on the chip with a scanner (iScan). The scanner reads information for each SNP examined – genotype and signal strength. Using special evaluation software, changes in CNV (Copy Number Variation) and neutral changes in AOH (Absence of Heterozygozity) are detected. The software virtually compares the patient’s data with the control group; control samples are not used for SNP array. Illumina chips with >700,000 markers are used for CNV and AOH analysis. The result is a report with cytogenetic notation of findings according to the current ISCN nomenclature. The report includes a comment on the result, a statement on the degree of pathogenicity of the findings (also taking into account clinical data on the family, patient/foetus) and recommendations for possible follow-up examinations. The report also includes the distinction of the method and its limitations.